Skip to library content
Back to the shelf
Peptide library
FDA-approvedDigestive & weight

Semaglutide

Evidence
Approved drug evidence
Class
GLP-1 receptor agonist

Semaglutide belongs to the GLP-1 receptor agonist class. This library groups it under digestive & weight. Its source category is FDA-approved.

Research libraryPeppy Care
Source snapshot
References18 linked sources

At a glance

Semaglutide research overview
Compound classGLP-1 receptor agonist
Associated brandsOzempic, Wegovy, Rybelsus
Body systemDigestive & weight
Use or research focusType 2 diabetes; chronic weight management; CV risk reduction
Regulatory statusFDA-approved
Source evidence ratingApproved drug evidence

How does Semaglutide work?

Activates GLP-1 receptor: boosts glucose-dependent insulin, slows gastric emptying, reduces appetite.

The source catalog maps this mechanism to Pancreas, Brain / CNS, Whole-body / Metabolic. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.

What does the evidence tell us?

This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.

Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.

Safety and considerations

An approved medicine can still have contraindications, interactions, and serious adverse effects. The current prescribing label is the place to check product-specific warnings. A clinician should review your medical history and other medicines before treatment.

This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.

Common questions

What is Semaglutide?

Semaglutide belongs to the GLP-1 receptor agonist class. This library groups it under digestive & weight. Its source category is FDA-approved. Its recorded use or research focus is: Type 2 diabetes; chronic weight management; CV risk reduction.

Is Semaglutide FDA-approved?

The catalog records: FDA-approved. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.

How strong is the research?

This record is associated with evidence for an approved drug. Approval applies to a specific formulation and indication; it does not extend to every use, combination, or compounded preparation. Check the regulatory details and linked prescribing information.

Where can I read the research?

The Citations tab contains 18 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.

More for digestive & weight

Factual catalog fields and citation links are adapted from Superpower’s Semaglutide guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.